Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. (2023)
Attributed to:
Biology and Treatment of Human Myeloid Cancers
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1200/jco.22.02604
PubMed Identifier: 37703506
Publication URI: http://europepmc.org/abstract/MED/37703506
Type: Journal Article/Review
Volume: 41
Parent Publication: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Issue: 31
ISSN: 0732-183X